Better Health,
Brighter Future
Newsroom
Careers
Investors
United States
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Takeda in the U.S.
Worldwide Offices
Executive Leadership
Corporate Philosophy
Contact Us
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Patient Services
U.S. Product List
Research & Development
Our Pipeline
Therapeutic Areas
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
In Their Shoes
The Key Elements at the Heart of Our Innovation
Partnerships as Catalysts for Innovation
Caring
Medicine for the World
Heritage
Keys to Aging Gracefully
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Commitment to Community
Our Environment
Culture of Compliance
Open Payments and Transparency Reporting
Federal
CPSIA
State
Diversity and Inclusion
Independent Medical Education Grants
Takeda Pricing Philosophy
Lobbying & Political Contributions
Patient Assistance
HOME
Newsroom
News Releases
Newsroom
News Releases
NATPARA Updates
News Releases
Enter
All
Last 12 months
2017
2016
2015
2014
2013
2012
February 2020
February 25, 2020
2/25/2020
Takeda Issues US Recall of Two Lots of VONVENDI
February 10, 2020
2/10/2020
Takeda to Present Research Advances in Rare Lysosomal Storage Disorders at 16th Annual WORLDSymposium™ 2020
December 2019
December 20, 2019
12/20/2019
Takeda Receives Complete Response Letter from U.S. FDA for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
December 13, 2019
12/13/2019
Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool
December 9, 2019
12/9/2019
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019
November 2019
November 6, 2019
11/6/2019
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
October 2019
October 28, 2019
10/28/2019
First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes
October 10, 2019
10/10/2019
Working Mother Names Takeda as One of the 2019 100 Best Companies
1
2
3
4
5
TOP
